Lung Neoplasms Clinical Trial
The purpose of our study is to determine whether contrast-enhanced dynamic MRI (DCE MRI) analysis of tumor angiogenesis and perfusion can be used as a reliable modality to differentiate benign from malignant solitary pulmonary nodules (SPN) before surgical intervention, using kinetic model derived from DCE MRI, and further correlate if there is any positive correlation between angiogenesis factor (vascular endothelial growth factor VEGF, microvessel density MVD); and if the perfusion parameters from DCE MRI can predict patients’ outcomes and survival.
The solitary pulmonary nodule (SPN) is a common finding in chest radiography. Pulmonary
nodules larger than 1cm indicative of malignancy or with indeterminate finding according to
morphology criteria have to be defined by invasive methods such as biopsy or surgical
excision, and benign pathology makes up 20-50% of those resected pulmonary lesions. The
lesions not receiving surgical intervention often need imaging follow-up on a regular basis
for a long period of time to monitor the stability of the finding.
There are many reports regarding the MRI perfusion analysis of neoplasms from many organs,
including bone marrow, liver, breast, cervix, and they stressed not only on comparison
between benignity and malignancy, but also on monitoring the treatment outcomes after
neoadjuvant chemotherapy, radiation therapy or anti-angiogenic agent therapy [7-15]. Dynamic
contrast-enhanced MRI (DCE MRI) is not a standard examination for SPN, but there have been
some data regarding the differentiation between malignant and benign SPN using DCE MRI, with
MRI offering higher specificity compared to dynamic CT scan [6, 7, 16]. It was also reported
that DCE MRI could delineate kinetic and morphologic differences in tumor angiogenesis and
perfusion characteristics between malignant and benign pulmonary lesions with relatively
high accuracy [7, 16]. The purpose of our study is to determine whether DCE MRI analysis of
tumor angiogenesis and perfusion can be used as a reliable modality to differentiate benign
from malignant SPN before surgical intervention, using kinetic model derived from DCE MRI,
and further correlate if there is any positive correlation between angiogenesis factor
(vascular endothelial growth factor VEGF, microvessel density MVD); and if the perfusion
parameters from DCE MRI can predict patients’ outcomes and survival.
;
Observational Model: Defined Population, Primary Purpose: Screening, Time Perspective: Cross-Sectional
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03357094 -
Pulmonary Ventilation/Perfusion Imaging for the Prediction of Postoperative Residual Pulmonary Function
|
N/A | |
| Recruiting |
NCT05543954 -
68Ga-FAPI-RGD PET/CT Imaging in the Lung Cancer Patients
|
Early Phase 1 | |
| Completed |
NCT01114958 -
Pilot Study of Intra-Arterial Cisplatin With IV Thiosulfate in Patients With Lung Cancer or Lung Metastases
|
Phase 1 | |
| Recruiting |
NCT06004440 -
Real World Registry for Use of the Ion Endoluminal System
|
||
| Not yet recruiting |
NCT02907606 -
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
|
N/A | |
| Completed |
NCT02926768 -
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02514512 -
Lung Cancer Radiotherapy Using Realtime Dynamic Multileaf Collimator (MLC) Adaptation And Radiofrequency Tracking
|
N/A | |
| Completed |
NCT02531737 -
Nintedanib (Vargatef®) Plus Docetaxel in Second Line of Treatment in Patients With Lung Cancer
|
Phase 2 | |
| Completed |
NCT02334007 -
Extended Low-Molecular Weight Heparin VTE Prophylaxis in Thoracic Surgery
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02284633 -
Blood Sample Monitoring of Patients With EGFR Mutated Lung Cancer
|
||
| Completed |
NCT02106143 -
RejuvenAir™ System Lobectomy Safety and Histology Study
|
N/A | |
| Completed |
NCT01933789 -
Improving Communication About Serious Illness
|
N/A | |
| Enrolling by invitation |
NCT01687647 -
Sputum Cytometry Analysis in Lung Cancer Screening After Professional Asbestos Exposure
|
Phase 3 | |
| Completed |
NCT00351962 -
Phase I/II Study of Fractionated Stereotactic Radiotherapy for Medically Inoperable NSCLC or Metastatic Lung Tumours
|
N/A | |
| Completed |
NCT00385177 -
Phase 1 Dose Escalation Study of SN2310 Injectable Emulsion in Patients With Advanced Solid Tumors
|
Phase 1 | |
| Completed |
NCT00243685 -
Chemotherapy Drug Sensitivity Microculture (MiCK) Assay for Apoptosis
|
Phase 2/Phase 3 | |
| Terminated |
NCT00356525 -
Chemotherapy Treatment in Re-occurring Non Small Cell Lung Cancer (NSCLC) After Previous Chemotherapy and Surgical Removal of the NSCLC Tumor
|
Phase 2 | |
| Completed |
NCT00129844 -
Study of Motexafin Gadolinium (MGd) for Second Line Treatment of Non-Small-Cell Lung Cancer
|
Phase 2 | |
| Withdrawn |
NCT00090701 -
A Phase 2, Open-Label, Multicenter Study of the GARFT Inhibitor in Patients With Metastatic Non-Small Cell Lung Cancer
|
Phase 2 | |
| Recruiting |
NCT01789229 -
Establishment of a Tumor Bank for Tissue Samples
|